AstraZeneca’s Post

This World Youth Skills Day, we want to recognise the young leaders and advocates around the world who are forging a healthier future within their communities. Through our Young Health Programme, we are creating a global youth health movement led by, and for, young people. By providing opportunities for their leadership development, scholarships, and funding, we can help develop and empower the next generation of change-makers in communities around the world. Learn more: https://learn.az/6045iuTKl #WorldYouthSkillsDay #YoungHealthProgramme

Intended for investors: Today, we’re pleased to announce the completion of AstraZeneca’s acquisition of Amolyt Pharma, a global biopharmaceutical company specialising in rare endocrine and related diseases. This acquisition bolsters the Alexion, AstraZeneca Rare Disease pipeline and enables us to reach more patients living with #RareDiseases. Read more: https://learn.az/6042iOVpM

As our research uncovers more subtypes and personalised treatments, clear communication about biomarkers with patients is increasingly crucial. Our global survey with ABC Global Alliance emphasises the need to empower people living with metastatic breast cancer with knowledge about biomarkers to engage in their care decisions. To learn more visit: https://learn.az/6048gBOaY

The Cambodia Breast Cancer Initiative is just one way we have collaborated with Americares since 2003. Thanks to the partnership more than 100,000 Cambodian women were reached with information, and 10,000 women were screened for breast cancer. Find out more here: https://learn.az/60459XceS #GlobalHealth #HealthcareForAll #PatientHealth

This recent publication in Nature Metabolism on preclinical disease models that better reflect Metabolic dysfunction-Associated Steatohepatitis (MASH) in humans aims to increase success of future clinical trials. It highlights a milestone in our collaboration with the LITMUS Project, of which we have been a member for several years. The LITMUS Project is a public-private partnership dedicated to advancing vital research efforts aimed at tackling MASH. Learn more here: https://learn.az/604891Kxn

We're thrilled to announce that for the second year in a row we have maintained our Gold rating for EcoVadis, the globally recognised sustainability rating platform. This achievement reflects our commitment to driving sustainability from lab to patient. Evaluating our performance in four key areas: environment, ethics, labour and human rights, and sustainable procurement, the result places us in the top 3% of all rated companies. Through our ambitious sustainability strategy, we’re focused on delivering positive impact for people, society and planet. Find out more in our Sustainability Impact publication: https://learn.az/6040goA2m #WhatScienceCanDo #Ecovadis 🌿 🌍

We're motivated by patients and our partners to address the realities of GI cancers and drive breakthroughs for those in need. We believe in inclusivity to help us reach our bold goal and look forward to working alongside members of the GI cancer community at #ESMOGI24 to revolutionise GI cancer care.

We have joined forces with International Gynecologic Cancer Society and their Advocacy Network, IGCAN, to share the stories of inspiring women impacted by uterine cancer around the world. Access the full video here https://learn.az/6048gdRJm #UterineCancerAwarenessMonth #EndometrialCancer #WombCancer

Advances in cell therapy are transforming cancer treatment; however, their revolutionary status leads to unique challenges for existing regulatory frameworks. We’re collaborating with regulators internationally to help shape frameworks that support patient access to these new, transformative cell therapies in oncology.   Learn more here: https://lnkd.in/esC9hQuW #WhatScienceCanDo #RegulatoryFrameworks #CellTherapy